https://www.businesswire.com/news/home/20260413254076/en/Enanta-Pharmaceuticals-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-EDP-978-an-Oral-Once-Daily-KIT-Inhibitor-in-Development-for-the-Treatment-of-Urticaria
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immuno...
https://www.benzinga.com/news/earnings/22/11/29785403/earnings-outlook-for-enanta-pharmaceuticals
Earnings Outlook For Enanta Pharmaceuticals - Enanta Pharma (NASDAQ:ENTA) - Benzinga
earnings outlookpharmaceuticalsnasdaqentabenzinga
https://pharma.economictimes.indiatimes.com/news/research-and-development/enantas-rsv-treatment-helps-speed-up-recovery-in-study-shares-surge/124223385
Enanta Pharmaceuticals: Enanta's RSV treatment helps speed up recovery in study, shares surge,...
Enanta Pharmaceuticals: All RSV symptoms in patients on zelicapavir resolved 2.2 days faster than a placebo, and 6.7 days faster in the high-risk group, which...
https://www.benzinga.com/quote/ENTA/guidance
Enanta Pharma Stock Guidance | NASDAQ:ENTA | Benzinga
Access expert guidance on Enanta Pharma stock with Benzinga. Stay informed on market forecasts, trends, and investment strategies for ENTA.
pharmastockguidancenasdaqenta